Understanding the Role of Janus Kinase in RA Pathogenesis to Appropriately Incorporate JAK Inhibition in RA Management
WebcastFaculty
OVERVIEW
Understanding the Role of Janus Kinase in RA Pathogenesis to Appropriately Incorporate JAK Inhibition in RA Management is organized by Global Academy For Medical Education and will be held Jun 01, 2017 - Jun 30, 2018.
The target audience for this medical event is Rheumatologists, internal medicine physicians with a secondary in rheumatology, physician assistants (PAs), nurse practitioners (NPs), and nurses in rheumatology, and other clinicians who treat patients with rheumatic diseases. This CME Conference has been approved for a maximum of .75 AMA PRA Category 1 Credits.
Course Description:
Current guidelines for the management of rheumatoid arthritis (RA) address the concern that many patients fail to respond, or lose response, to first-line therapy with disease-modifying antirheumatic drugs (DMARDs). Lack of understanding about the optimal use of available RA therapies – including combination therapy or switching to other drugs within a class or in a different class – means that many patients may fail to achieve remission (the ideal goal) or minimal levels of disease activity. Clinicians who are unaware of current practice guidelines may not be providing optimal management of their patients with RA. In addition, clinicians should be aware of data concerning the safety and efficacy of newly available drugs so as to ensure selection of optimal therapies for patients with RA. Knowledge of agents that have novel mechanisms of action, including Janus kinase inhibitors, can improve clinicians’ confidence when switching therapies in patients who have suboptimal response despite appropriate use of DMARD therapies.
Course Objectives:
By participating in this activity, you should be better able to:
• Design optimal treatment strategies for patients with rheumatoid arthritis (RA) to improve remission rates and/or minimize levels of disease
• Recognize the role that Janus kinase (JAK) plays in the pathogenesis of RA and the corresponding impact of JAK inhibition in the management of RA
• Discuss treatment options for RA, including the use of JAK inhibitors, as reflected in current practice guidelines
Additional details will be posted as soon as they are available.
The target audience for this medical event is Rheumatologists, internal medicine physicians with a secondary in rheumatology, physician assistants (PAs), nurse practitioners (NPs), and nurses in rheumatology, and other clinicians who treat patients with rheumatic diseases. This CME Conference has been approved for a maximum of .75 AMA PRA Category 1 Credits.
Course Description:
Current guidelines for the management of rheumatoid arthritis (RA) address the concern that many patients fail to respond, or lose response, to first-line therapy with disease-modifying antirheumatic drugs (DMARDs). Lack of understanding about the optimal use of available RA therapies – including combination therapy or switching to other drugs within a class or in a different class – means that many patients may fail to achieve remission (the ideal goal) or minimal levels of disease activity. Clinicians who are unaware of current practice guidelines may not be providing optimal management of their patients with RA. In addition, clinicians should be aware of data concerning the safety and efficacy of newly available drugs so as to ensure selection of optimal therapies for patients with RA. Knowledge of agents that have novel mechanisms of action, including Janus kinase inhibitors, can improve clinicians’ confidence when switching therapies in patients who have suboptimal response despite appropriate use of DMARD therapies.
Course Objectives:
By participating in this activity, you should be better able to:
• Design optimal treatment strategies for patients with rheumatoid arthritis (RA) to improve remission rates and/or minimize levels of disease
• Recognize the role that Janus kinase (JAK) plays in the pathogenesis of RA and the corresponding impact of JAK inhibition in the management of RA
• Discuss treatment options for RA, including the use of JAK inhibitors, as reflected in current practice guidelines
Additional details will be posted as soon as they are available.
SPECIALITIES
PathologyRELATED ONLINE COURSES
Quick Links